Hyperfine, INC 8-K filings

Hyperfine, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the reelection of directors and ratification of its independent auditor.

Hyperfine, Inc. announced first quarter 2026 financial results, showcasing over 80% year-over-year revenue growth and improved gross margins, driven by accelerating commercial adoption of its portable brain imaging system.

Hyperfine, Inc. has secured a senior secured term loan facility of up to $40.0 million from Horizon Technology Finance Corporation, with an initial draw of $15.0 million and issuance of warrants.

Hyperfine, Inc. announced strong fourth-quarter 2025 revenue growth of 128% and a reduced net loss, driven by increased Swoop system sales and strategic capital raises.

Hyperfine, Inc. announced preliminary, unaudited fourth quarter 2025 revenue of $5.3 million, a 127% increase year-over-year, alongside a 30% reduction in net cash burn.

Hyperfine, Inc. has amended its at-the-market sales agreement, increasing the potential offering to $50 million and adding BTIG, LLC as a sales agent for its Class A common stock.

Hyperfine, Inc. reported a 27% sequential revenue increase in Q3 2025, driven by the successful launch of its next-generation Swoop system and Optive AI software.

Hyperfine, Inc. announced the pricing of an underwritten public offering of 14 million Class A common shares at $1.25 each, aiming to raise $17.5 million in gross proceeds for working capital and general corporate purposes.

Hyperfine, Inc. announced preliminary third-quarter 2025 financial results, showcasing strong sequential revenue growth and reduced cash burn driven by the successful launch of its next-generation Swoop system.

Hyperfine, Inc. announced second quarter 2025 financial results, highlighting sequential revenue growth, improved gross margins, and key FDA clearances for its AI-powered Swoop system.

Hyperfine, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported non-compliance matter.

Hyperfine, Inc. announced a leadership transition with R. Scott Huennekens resigning as Chairperson of the Board for personal reasons, effective May 22, 2025, and current board member Daniel J. Wolterman being appointed as the new Chairperson.

Hyperfine, Inc. held its 2025 annual meeting of stockholders on May 19, 2025, where stockholders voted on two proposals.

Hyperfine, Inc. announces its first quarter 2025 financial results, highlighting progress in expanding its pipeline and upcoming FDA clearances.

Hyperfine, Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement, putting its listing at risk.

Hyperfine, Inc. announces its fourth quarter and full year 2024 financial results, showcasing revenue growth, strategic cost reductions, and advancements in its portable MR imaging technology.

Hyperfine, Inc. has entered into a definitive agreement for a registered direct offering of shares and warrants, expected to generate approximately $6.0 million in gross proceeds.

Hyperfine, Inc. reports preliminary unaudited 2024 financial results, including $12.9 million in total revenue and $37.6 million in cash, while outlining growth strategies for 2025.

Hyperfine, Inc. is implementing a restructuring plan that includes a 14% workforce reduction to streamline operations and extend its cash runway into the second half of 2026.

Hyperfine, Inc. announced record third-quarter revenue of $3.64 million, a 56% increase year-over-year, alongside gross margin expansion and disciplined cash management.

Hyperfine, Inc. announced record quarterly revenue of $3.63 million and raised its full-year revenue guidance to $13-16 million.

Hyperfine Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price rose above $1.00 per share.

Hyperfine Inc. has amended its charter to include a provision for the automatic conversion of Class B common stock to Class A common stock on December 22, 2028.

Hyperfine, Inc. has received a notice from Nasdaq stating that its stock price has fallen below the minimum bid price requirement for continued listing.

Hyperfine Inc. announced a 25% increase in revenue for the first quarter of 2024, alongside key milestones in clinical studies and software development.

Hyperfine, Inc. announced a 62% increase in full-year revenue and a significant reduction in cash burn for 2023, alongside advancements in their portable MRI technology.